COVID-19 trials registries data warehouse

https://jrct.niph.go.jp/latest-detail/jRCTs051200049

Yukio Tanaka

yukiotanaka@dmi.med.osaka-u.ac.jp

2020-08-26

Not recruiting

RCT

Randomized

Parallel

Open label

multi-center

Treatment

1) Patients who are positive for SARS-CoV-2 by PCR or antigen test 2) Patients who do not need continuous (24h) oxygen inhalation3) Patients who can eat and drink4) Patients older or equal to 20 years old and younger than 75 years old5) Patients who can sign the informed consent form by themselves

1) Patients with hypersensitivity for tetracycline compound2) Patients showing SpO2 < 93% without oxygen inhalation3) Patients who are or have a possibility to be pregnant, or hope to be pregnant during the study.4) Patients with liver failure (AST and/or ALT >= the standard value)5) Patients with kidney failure (eGFR < 30 ml/min/1.73m2)6) Patients who had a COVID-19 vaccination7) Patients who are considered unsuitable for the study by the PI or sub investigators

3

Iwahori Kota

20

75

Japan

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

42

The change rate of CD8+ T cells between before and 7 days after the administration of the study drug

Phase 2

[{"arm_notes": "150mg day for 14 days", "treatment_id": 396, "treatment_name": "Demethylchlortetracycline", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "300mg day for 14 days", "treatment_id": 396, "treatment_name": "Demethylchlortetracycline", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]